Publication: Reduced nicotinamide mononucleotide is a new and potent NAD+ precursor in mammalian cells and mice
| dc.contributor.author | Zapata- Pérez, Rubén | |
| dc.contributor.author | Tammaro, Alessandra | |
| dc.contributor.author | Schomakers, Bauke V. | |
| dc.contributor.author | Scantlebery, Angelique M. L. | |
| dc.contributor.author | Denis, Simone | |
| dc.contributor.author | Elfrink, Hyung L. | |
| dc.contributor.author | Giroud- Gerbetant, Judith | |
| dc.contributor.author | Cantó, Carles | |
| dc.contributor.author | López Leonardo, Carmen | |
| dc.contributor.author | McIntyre, Rebecca L. | |
| dc.contributor.author | Weeghel, Michel van | |
| dc.contributor.author | Sánchez Ferrer, Álvaro | |
| dc.contributor.author | Houtkooper, Riekelt H. | |
| dc.contributor.department | Química Orgánica | |
| dc.contributor.department | Bioquímica y Biología Molecular A | |
| dc.contributor.other | Facultad de Química | |
| dc.contributor.other | Facultad de Veterinaria | |
| dc.date.accessioned | 2025-12-17T08:16:12Z | |
| dc.date.available | 2025-12-17T08:16:12Z | |
| dc.date.copyright | © 2021 The Authors | |
| dc.date.issued | 2021-03-16 | |
| dc.description.abstract | Nicotinamide adenine dinucleotide (NAD+) homeostasis is constantly compromised due to degradation by NAD+-dependent enzymes. NAD+ replenishment by supplementation with the NAD+ precursors nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR) can alleviate this imbalance. However, NMN and NR are limited by their mild effect on the cellular NAD+ pool and the need of high doses. Here, we report a synthesis method of a reduced form of NMN (NMNH), and identify this molecule as a new NAD+ precursor for the first time. We show that NMNH increases NAD+ levels to a much higher extent and faster than NMN or NR, and that it is metabolized through a different, NRK and NAMPT-independent, pathway. We also demonstrate that NMNH reduces damage and accelerates repair in renal tubular epithelial cells upon hypoxia/reoxygenation injury. Finally, we find that NMNH administration in mice causes a rapid and sustained NAD+ surge in whole blood, which is accompanied by increased NAD+ levels in liver, kidney, muscle, brain, brown adipose tissue, and heart, but not in white adipose tissue. Together, our data highlight NMNH as a new NAD+ precursor with therapeutic potential for acute kidney injury, confirm the existence of a novel pathway for the recycling of reduced NAD+ precursors and establish NMNH as a member of the new family of reduced NAD+ precursors. | |
| dc.format | application/pdf | |
| dc.format.extent | 17 | |
| dc.identifier.citation | The FASEB Journal. 2021;35:e21456 | |
| dc.identifier.doi | https://doi.org/10.1096/fj.202001826R | |
| dc.identifier.eissn | 1530-6860 | |
| dc.identifier.issn | 0892-6638 | |
| dc.identifier.uri | http://hdl.handle.net/10201/180749 | |
| dc.language | eng | |
| dc.publisher | Wiley | |
| dc.relation | The authors would like to thank Loes Butter for assistance with hypoxia/reoxygenation assays. AT is financially supported by the NWO-FAPESP joint grant on healthy ageing, executed by ZonMw (no. 457002002). RZP is supported by a postdoctoral grant from the European Union's Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement number 840110. Work in the Houtkooper group is financially supported by an ERC Starting grant (no. 638290), a VIDI grant from ZonMw (no. 91715305), and a grant from the Velux Stiftung (no. 1063). ASF group is supported by Spanish grants from MINECO-FEDER (BIO2013-45336- R) and from Ayudas a los Grupos y Unidades de Excelencia Científica de la Región de Murcia, Fundación Séneca-Agencia de Ciencia y Tecnología de la Región de Murcia (19893/GERM/15, Programa de Apoyo a la Investigación 2014). | |
| dc.relation.publisherversion | https://faseb.onlinelibrary.wiley.com/doi/10.1096/fj.202001826R | |
| dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International | * |
| dc.rights.accessRights | info:eu-repo/semantics/openAccess | |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
| dc.subject | Metabolism | |
| dc.subject | NAD+ | |
| dc.subject | NMNH | |
| dc.subject | Nicotinamide mononucleotide | |
| dc.subject.ods | No relacionado con ningún objetivo de desarrollo sostenible | |
| dc.title | Reduced nicotinamide mononucleotide is a new and potent NAD+ precursor in mammalian cells and mice | |
| dc.type | info:eu-repo/semantics/article | |
| dc.type.version | info:eu-repo/semantics/publishedVersion | |
| dspace.entity.type | Publication | es |
| relation.isAuthorOfPublication | 434dc353-54ab-4dcc-b277-61e489ca79d6 | |
| relation.isAuthorOfPublication | 434dc353-54ab-4dcc-b277-61e489ca79d6 | |
| relation.isAuthorOfPublication | aa6ca3f7-ee95-4c3b-b93d-82bbb7c57dd3 | |
| relation.isAuthorOfPublication.latestForDiscovery | 434dc353-54ab-4dcc-b277-61e489ca79d6 |
Collections
Este ítem está sujeto a una licencia Creative Commons. http://creativecommons.org/licenses/by-nc-nd/4.0/